This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lounis, N. Articles by Andries, K. Search for Related Content PubMed PubMed Citation Articles by Lounis, N. Articles by Andries, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3568-3572, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00566-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse Model

Nacer Lounis,^* Tom Gevers, Joke Van Den Berg, and Koen Andries

Department of Antimicrobial Research, Tibotec BVBA, Johnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium

Received 30 April 2008/ Returned for modification 5 June 2008/ Accepted 11 July 2008

New drugs are needed to shorten the duration of tuberculosis treatment. R207910, a diarylquinoline, is very active against Mycobacterium tuberculosis both in vitro and in mice. In healthy volunteers, the coadministration of R207910 and rifampin induced the increased metabolism of R207910, resulting in a 50% reduction in the level of R207910 exposure. We assessed the impact of reducing the dose of R207910 on its efficacy when R207910 was combined with a background regimen of isoniazid, rifampin, and pyrazinamide. Addition of 25 mg/kg of body weight or 12.5 mg/kg R207910 to the background regimen resulted in faster bacterial clearance and culture negativity. The difference in efficacy between the two doses was not statistically significant. The minimal bactericidal dose of R207910 when it was tested as part of the combination was identical to that when it was tested as monotherapy. Because of the drug-drug interaction in humans, the activity of R207910 in humans could be less than that expected from studies with mice. Our data from the mouse model demonstrate that R207910 has significant activity, even when its exposure is reduced by 50% and when it is added to a strong background regimen of isoniazid, rifampin, and pyrazinamide. In killing kinetic studies, the bactericidal effect of R207910 in mice was modest during the first week of treatment, but it increased in the following 3 weeks, while the bactericidal activity of isoniazid was limited to the first week of treatment.

---

* Corresponding author. Mailing address: Tibotec BVBA, Johnson & Johnson, Turnhoutseweg 30, Beerse 2340, Belgium. Phone: 32 14 60 65 71. Fax: 32 14 60 54 03. E-mail: nlounis{at}tibbe.jnj.com

Published ahead of print on 21 July 2008.

---

Antimicrobial Agents and Chemotherapy, October 2008, p. 3568-3572, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00566-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
• Yew, W. W., Leung, C. C. (2009). Update in Tuberculosis 2008. Am. J. Respir. Crit. Care Med. 179: 337-343 [Full Text]  
• Hong, S., Pedersen, P. L. (2008). ATP Synthase and the Actions of Inhibitors Utilized To Study Its Roles in Human Health, Disease, and Other Scientific Areas. Microbiol. Mol. Biol. Rev. 72: 590-641 [Abstract] [Full Text]